Clinical Trials Directory

Trials / Completed

CompletedNCT03950258

Endovascular Management of Pediatric Intracranial Arteriovenous Shunts

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

* Review the outcomes of the Endovascular management of pediatric intracranial arteriovenous shunts. * Give an effective treatment for pediatric intracranial arteriovenous shunts and can detect the best method could be used and assess safety and efficacy of different endovascular techniques in treatment of different AV shunts. * Improve the outcome of these patients and decease rate of recurrence and complications.

Detailed description

Intracranial arteriovenous shunts (ICAVS) in young children are characterized by frequent high-flow fistulas. In association with high-flow fistulas and the physiological condition of the developing brain and heart, each ICAVS type tends to present at a certain age with unique symptoms. Vein of Galen aneurysmal malformation (VGAM) and dural sinus malformation with arteriovenous (AV) shunt tend to present in the neonate with high output cardiac failure. In infancy, VGAM, pial arteriovenous fistula (AVF) and infantile dural AVF (DAVF) tend to present with hydrodynamic disorder such as macrocephaly, ventriculomegaly, prominent facial veins, and developmental delay. Pial AVF, AV malformation, and infantile DAVF can present with focal neurological signs such as seizure or hemorrhage at older ages they are in the subpial space, as opposed to VGAM or DAVF, which are extrapial in location and tend to present with systemic symptoms . Endovascular treatment is currently the first choice of treatment for most pediatric ICAVS. The treatment goal should be defined on a patient-by-patient basis, according to the unique physiological condition of the child.

Conditions

Interventions

TypeNameDescription
PROCEDUREendovascular embolizationTransarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.

Timeline

Start date
2019-07-01
Primary completion
2020-05-05
Completion
2020-05-05
First posted
2019-05-15
Last updated
2020-05-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03950258. Inclusion in this directory is not an endorsement.